RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재

      특허권과 개발도상국에서의 의약품에 대한 접근과의 조화를 위한 모색 : TRIPS 협정과 그 이 후

      한글로보기

      https://www.riss.kr/link?id=A101888579

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Since the 1995 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) there has been a growing tension in developing countries between the right of patients to access affordable medicines and the obligation to protect the patent rights of the pharmaceutical companies. This tension has arguably led to a growing crisis in public health in developing countries. This article examines this issue in six parts; following an introduction, part Ⅱ summarizes the tension between patent rights and patient rights. Part Ⅲ highlights the flexibilities created by TRIPS and its subsequent amendment that aim to mitigate the potentially negative consequences of patenting on access to medicines. This part explains the system of compulsory licensing that allows third parties to produce and sell patented drugs without the consent of the rights holder, so long as governments follow certain procedures. In addition, the system of parallel imports is examined under TRIPS. Despite these flexibilities, many developing countries have failed to take advantage of this flexibility by not incorporating the appropriate provisions into national law. Parts Ⅳ and Ⅴ examine three of the reasons constraining access to medicines in developing countries. The first is a problem over Article 31(f) of TRIPS that is restricted to domestic market supply. The second is a problem of the uncertainty over the scope of Article 31 of TRIPS. It appears that through a combination of political pressure, legal challenges and other tactics, the pro-pharmaceutical company lobby has sought to prevent developing countries from exercising their rights under TRIPS. To address these problems, the "Doha Declaration on TRIPS and Public Health" and an unprecedented subsequent amendment to TRIPS in 2005 reinforced the original agreement. The third reason is the threat to compulsory licensing via regional or bilateral pressure, particularly when exerted through free trade agreements (FTAs). Such agreements have introduced so-called "TRIPS-plus" measures such as "data exclusivity" and "marketing approval/patent linkage" provisions that have the potential to constrain the ability of developing countries to use compulsory licensing. This section also looks at these TRIPS-plus measures within the recent Korea/US FTA. Part Ⅵ concludes that without a greater sense of global responsibility by developed countries and pharmaceutical companies, the combination of TRIPS and FTAs could prove a hindrance to improving public health in the developing world.
      번역하기

      Since the 1995 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) there has been a growing tension in developing countries between the right of patients to access affordable medicines and the obligati...

      Since the 1995 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) there has been a growing tension in developing countries between the right of patients to access affordable medicines and the obligation to protect the patent rights of the pharmaceutical companies. This tension has arguably led to a growing crisis in public health in developing countries. This article examines this issue in six parts; following an introduction, part Ⅱ summarizes the tension between patent rights and patient rights. Part Ⅲ highlights the flexibilities created by TRIPS and its subsequent amendment that aim to mitigate the potentially negative consequences of patenting on access to medicines. This part explains the system of compulsory licensing that allows third parties to produce and sell patented drugs without the consent of the rights holder, so long as governments follow certain procedures. In addition, the system of parallel imports is examined under TRIPS. Despite these flexibilities, many developing countries have failed to take advantage of this flexibility by not incorporating the appropriate provisions into national law. Parts Ⅳ and Ⅴ examine three of the reasons constraining access to medicines in developing countries. The first is a problem over Article 31(f) of TRIPS that is restricted to domestic market supply. The second is a problem of the uncertainty over the scope of Article 31 of TRIPS. It appears that through a combination of political pressure, legal challenges and other tactics, the pro-pharmaceutical company lobby has sought to prevent developing countries from exercising their rights under TRIPS. To address these problems, the "Doha Declaration on TRIPS and Public Health" and an unprecedented subsequent amendment to TRIPS in 2005 reinforced the original agreement. The third reason is the threat to compulsory licensing via regional or bilateral pressure, particularly when exerted through free trade agreements (FTAs). Such agreements have introduced so-called "TRIPS-plus" measures such as "data exclusivity" and "marketing approval/patent linkage" provisions that have the potential to constrain the ability of developing countries to use compulsory licensing. This section also looks at these TRIPS-plus measures within the recent Korea/US FTA. Part Ⅵ concludes that without a greater sense of global responsibility by developed countries and pharmaceutical companies, the combination of TRIPS and FTAs could prove a hindrance to improving public health in the developing world.

      더보기

      목차 (Table of Contents)

      • I. 머리말
      • II. 의약품에 대한 접근 vs. 의약품에 대한 특허권
      • 1. 의약품에 대한 접근이 문제되는 2가지 경우
      • 2. 의약품 접근에 대한 권리의 근거
      • 3. 의약품에 대한 특허권
      • I. 머리말
      • II. 의약품에 대한 접근 vs. 의약품에 대한 특허권
      • 1. 의약품에 대한 접근이 문제되는 2가지 경우
      • 2. 의약품 접근에 대한 권리의 근거
      • 3. 의약품에 대한 특허권
      • 4. 의약품에 대한 특허권과 의약품에 접근할 권리간의경합 현상
      • Ⅲ. 특허권의 제한
      • 1. 강제실시에 의한 특허권의 제한
      • 2. 병행수입에 의한 특허권의 제한
      • IV. 특허권의 제한에 대한 TRIPS 협정 규정상의 문제점들
      • 1. 문제점 1: TRIPS 협정 제31(f)조 국내실시 규정
      • 2. 문제점 2: TRIPS 협정 제31조의 불명확한 범위와적용
      • 3. 문제점 3: TRIPS-plus와 FTA
      • V. FTA상의 강제실시제도의 실효성에 영향을미칠 수 있는 조항들
      • 1. 의약품 시판허가/특허 연계: 식약청과 특허청 업무의연계
      • 2. 자료독점권
      • VI. 맺음말
      • 참고문헌
      • ABSTRACT
      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼